Regulatory support for Choroideremia treatment from Nightstar
Nightstar, a spin-out from the University of Oxford in 2014 has received both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Orphan Drug Designation for its lead programme, a gene therapy to treat Choroideremia, an X-linked recessive disorder that leads to progressive blindness.